These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25351635)

  • 1. Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor.
    Montagnani Marelli M; Manea M; Moretti RM; Marzagalli M; Limonta P
    Int J Oncol; 2015 Jan; 46(1):243-53. PubMed ID: 25351635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced cellular uptake and in vitro antitumor activity of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates.
    Hegedüs R; Manea M; Orbán E; Szabó I; Kiss E; Sipos E; Halmos G; Mező G
    Eur J Med Chem; 2012 Oct; 56():155-65. PubMed ID: 22967796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.
    Leurs U; Lajkó E; Mező G; Orbán E; Öhlschläger P; Marquardt A; Kőhidai L; Manea M
    Eur J Med Chem; 2012 Jun; 52():173-83. PubMed ID: 22480495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice.
    Manea M; Tóvári J; Tejeda M; Schulcz A; Kapuvári B; Vincze B; Mezo G
    Anticancer Drugs; 2012 Jan; 23(1):90-7. PubMed ID: 21915040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro degradation and antitumor activity of oxime bond-linked daunorubicin-GnRH-III bioconjugates and DNA-binding properties of daunorubicin-amino acid metabolites.
    Orbán E; Mezo G; Schlage P; Csík G; Kulić Z; Ansorge P; Fellinger E; Möller HM; Manea M
    Amino Acids; 2011 Jul; 41(2):469-83. PubMed ID: 20953647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, enzymatic stability and in vitro cytostatic effect of Daunorubicin-GnRH-III derivative dimers.
    Schreier VN; Mező G; Orbán E; Dürr C; Marquardt A; Manea M
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2145-50. PubMed ID: 23434423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced enzymatic stability and antitumor activity of daunorubicin-GnRH-III bioconjugates modified in position 4.
    Manea M; Leurs U; Orbán E; Baranyai Z; Öhlschläger P; Marquardt A; Schulcz Á; Tejeda M; Kapuvári B; Tóvári J; Mezo G
    Bioconjug Chem; 2011 Jul; 22(7):1320-9. PubMed ID: 21668011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice.
    Kapuvári B; Hegedüs R; Schulcz Á; Manea M; Tóvári J; Gacs A; Vincze B; Mező G
    Invest New Drugs; 2016 Aug; 34(4):416-23. PubMed ID: 27146514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug.
    Szabó I; Manea M; Orbán E; Csámpai A; Bosze S; Szabó R; Tejeda M; Gaál D; Kapuvári B; Przybylski M; Hudecz F; Mezo G
    Bioconjug Chem; 2009 Apr; 20(4):656-65. PubMed ID: 19296605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved In Vivo Anti-Tumor and Anti-Metastatic Effect of GnRH-III-Daunorubicin Analogs on Colorectal and Breast Carcinoma Bearing Mice.
    Ranđelović I; Schuster S; Kapuvári B; Fossati G; Steinkühler C; Mező G; Tóvári J
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31557968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro biological evaluation of daunorubicin containing GnRH-I and GnRH-II conjugates developed for tumor targeting.
    Szabó I; Bősze S; Orbán E; Sipos É; Halmos G; Kovács M; Mező G
    J Pept Sci; 2015 May; 21(5):426-35. PubMed ID: 25908176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthracycline-GnRH derivative bioconjugates with different linkages: synthesis, in vitro drug release and cytostatic effect.
    Schlage P; Mezo G; Orbán E; Bosze S; Manea M
    J Control Release; 2011 Dec; 156(2):170-8. PubMed ID: 21864594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies.
    Limonta P; Manea M
    Cancer Treat Rev; 2013 Oct; 39(6):647-63. PubMed ID: 23290320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of daunorubicin-GnRH-III bioconjugates with oligoethylene glycol derivatives to improve solubility and bioavailability for targeted cancer chemotherapy.
    Hegedüs R; Pauschert A; Orbán E; Szabó I; Andreu D; Marquardt A; Mező G; Manea M
    Biopolymers; 2015 May; 104(3):167-77. PubMed ID: 25753049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Biochemical Characterization of Self-Immolative Linker Containing GnRH-III-Drug Conjugates.
    Schuster S; Juhász É; Halmos G; Neundorf I; Gennari C; Mező G
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. lGnRH-III -- a promising candidate for anticancer drug development.
    Manea M; Mező G
    Protein Pept Lett; 2013 Apr; 20(4):439-49. PubMed ID: 23016589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type I gonadotropin-releasing hormone receptor mediates the antiproliferative effects of GnRH-II on prostate cancer cells.
    Montagnani Marelli M; Moretti RM; Mai S; Januszkiewicz-Caulier J; Motta M; Limonta P
    J Clin Endocrinol Metab; 2009 May; 94(5):1761-7. PubMed ID: 19190109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein expression profile of HT-29 human colon cancer cells after treatment with a cytotoxic daunorubicin-GnRH-III derivative bioconjugate.
    Schreier VN; Pethő L; Orbán E; Marquardt A; Petre BA; Mező G; Manea M
    PLoS One; 2014; 9(4):e94041. PubMed ID: 24718594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin-GnRH-III conjugates developed for targeted drug delivery.
    Schuster S; Biri-Kovács B; Szeder B; Farkas V; Buday L; Szabó Z; Halmos G; Mező G
    Beilstein J Org Chem; 2018; 14():756-771. PubMed ID: 29719573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation on chemotactic drug targeting (chemotaxis and adhesion) inducer effect of GnRH-III derivatives in Tetrahymena and human leukemia cell line.
    Lajkó E; Szabó I; Andódy K; Pungor A; Mező G; Kőhidai L
    J Pept Sci; 2013 Jan; 19(1):46-58. PubMed ID: 23208929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.